Processa Pharmaceuticals secured $200 million in private placement funding and added a clinical-stage BTK inhibitor pipeline via acquisition.
1 report, 1 independent
Updated Jul 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Processa Pharmaceuticals secured $200 million in private placement funding and added a clinical-stage BTK inhibitor pipeline via acquisition.